CrowdStrike vs. UiPath: Which Technology Stock Is a Better Buy in 2026?

CrowdStrike reported FY2026 revenue of nearly $4.8B, up 21.7% year over year, but posted a $162.5M net loss and trades at a steep 146.6x forward P/E and 39.3x sales. UiPath generated nearly $1.6B of revenue, up 12.7%, and achieved $282.3M of net income for a 17.5% margin, while trading at 15.9x forward P/E and 4.2x sales. The article nevertheless favors CrowdStrike for record ARR, free cash flow nearing one-third of revenue, AI-related cybersecurity demand, and platform expansion, while noting litigation, reputational, and competitive risks.

Analysis

The relevant divergence is not cybersecurity versus automation but durable security consolidation versus a turnaround being valued as durable. CRWD's premium requires sustained growth plus continued module expansion; at this valuation, even modest deceleration or a lower net-retention trajectory can produce material multiple compression. The OpenAI linkage is strategically useful but should not be capitalized as incremental revenue until attach rates, pricing, and enterprise adoption are disclosed; AMZN remains a more diversified, lower-beta beneficiary of security workload growth.

PATH's low multiple reflects skepticism that recent GAAP profitability is repeatable after acquisition integration, rather than simply an overlooked AI asset. Its more compelling setup is operating leverage: if agentic automation converts from pilots into broader deployments, incremental revenue should carry materially higher margins than its historical services-heavy growth. The key risk over the next 1-3 quarters is that Microsoft (MSFT), ServiceNow (NOW), and Salesforce (CRM) bundle comparable workflow/agent functionality into existing enterprise contracts, limiting PATH's pricing power and renewal expansion.

Near term, CRWD is vulnerable to a high bar around ARR, net-new module adoption, and any residual customer-liability or retention disclosures; the market is likely to reward beats less than it punishes evidence of normalization. Over 6-18 months, AI expands both attack surface and automation demand, but security spend is generally mission-critical while automation budgets remain more discretionary. The contrarian view is that consensus is treating PATH's depressed valuation as proof of inferior economics, while it may instead be pricing a transition period; conversely, CRWD's valuation leaves little room for execution that is merely excellent.

Key Decisions for Investors

• Initiate a 1-3 month relative-value position: long PATH / short CRWD, sized beta-neutral. The valuation dispersion offers asymmetric upside if PATH sustains profitable growth or CRWD guides to even modest growth normalization; stop if PATH's next reported ARR/revenue growth decelerates below low-teens or management reduces profitability guidance.
• For cybersecurity exposure, prefer a smaller CRWD position only after earnings or material pullback rather than chasing pre-results. Add only if net retention/module adoption supports reacceleration; exit on evidence of elevated churn, new material crash-related reserves, or forward growth guidance below expectations.
• Use AMZN as the lower-volatility AI-security infrastructure expression over the next 6-18 months: AWS security workload growth can benefit without requiring a single-vendor security multiple to hold. This is preferable to treating the OpenAI partnership as a standalone CRWD earnings catalyst.
• Set an alert around PATH's next earnings for disclosed enterprise expansion, large-customer concentration, and acquisition contribution. A beat driven by acquired revenue without improvement in organic retention or operating margin is not thesis confirmation and argues against adding.